Cover Image
市場調查報告書

ORCA Therapeutics B.V.的產品平台分析

ORCA Therapeutics B.V. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 318953
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
ORCA Therapeutics B.V.的產品平台分析 ORCA Therapeutics B.V. - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 23 Pages
簡介

ORCA Therapeutics B.V.是總公司設置於荷蘭的生物製藥企業,正在開發設計基於可造成腫瘤崩壞的可複製媒體(ORCA)之抗癌劑。ORCA是天然病毒所製,可破壞癌細胞及腫瘤細胞。

本報告提供ORCA Therapeutics B.V.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

ORCA Therapeutics B.V.的基本資料

  • ORCA Therapeutics B.V.概要
  • 主要資訊
  • 企業資料

ORCA Therapeutics B.V.:R&D概要

  • 主要的治療範圍

ORCA Therapeutics B.V.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

ORCA Therapeutics B.V.:開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

ORCA Therapeutics B.V.:藥物簡介

  • ORCA-010
  • Oncolytic Viruses to Activate p53 for Cancer
  • Oncolytic Virus for Cancer

ORCA Therapeutics B.V.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

ORCA Therapeutics B.V.:開發暫停中的計劃

ORCA Therapeutics B.V.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07648CDB

Summary

Global Markets Direct's, 'ORCA Therapeutics B.V. - Product Pipeline Review - 2015', provides an overview of the ORCA Therapeutics B.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ORCA Therapeutics B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ORCA Therapeutics B.V. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ORCA Therapeutics B.V.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ORCA Therapeutics B.V.'s pipeline products

Reasons to buy

  • Evaluate ORCA Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ORCA Therapeutics B.V. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ORCA Therapeutics B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ORCA Therapeutics B.V. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ORCA Therapeutics B.V.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ORCA Therapeutics B.V. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ORCA Therapeutics B.V. Snapshot
    • ORCA Therapeutics B.V. Overview
    • Key Information
    • Key Facts
  • ORCA Therapeutics B.V. - Research and Development Overview
    • Key Therapeutic Areas
  • ORCA Therapeutics B.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ORCA Therapeutics B.V. - Pipeline Products Glance
    • ORCA Therapeutics B.V. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ORCA Therapeutics B.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ORCA Therapeutics B.V. - Drug Profiles
    • ORCA-010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncolytic Viruses to Activate p53 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncolytic Virus for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ORCA Therapeutics B.V. - Pipeline Analysis
  • ORCA Therapeutics B.V. - Pipeline Products by Target
  • ORCA Therapeutics B.V. - Pipeline Products by Molecule Type
  • ORCA Therapeutics B.V. - Pipeline Products by Mechanism of Action
  • ORCA Therapeutics B.V. - Dormant Projects
  • ORCA Therapeutics B.V. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ORCA Therapeutics B.V., Key Information
  • ORCA Therapeutics B.V., Key Facts
  • ORCA Therapeutics B.V. - Pipeline by Indication, 2015
  • ORCA Therapeutics B.V. - Pipeline by Stage of Development, 2015
  • ORCA Therapeutics B.V. - Monotherapy Products in Pipeline, 2015
  • ORCA Therapeutics B.V. - Phase I, 2015
  • ORCA Therapeutics B.V. - Preclinical, 2015
  • ORCA Therapeutics B.V. - Discovery, 2015
  • ORCA Therapeutics B.V. - Pipeline by Target, 2015
  • ORCA Therapeutics B.V. - Pipeline by Molecule Type, 2015
  • ORCA Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2015
  • ORCA Therapeutics B.V. - Dormant Developmental Projects,2015
  • ORCA Therapeutics B.V., Other Locations

List of Figures

  • ORCA Therapeutics B.V. - Pipeline by Top 10 Indication, 2015
  • ORCA Therapeutics B.V. - Pipeline by Stage of Development, 2015
  • ORCA Therapeutics B.V. - Monotherapy Products in Pipeline, 2015
  • ORCA Therapeutics B.V. - Pipeline by Top 10 Molecule Type, 2015
Back to Top